Overview

It Simply Works.

C2 Therapeutics was founded a decade ago to offer a new standard for simplicity in the ablation of esophageal disease. Our technology – the C2 CryoBalloon® Ablation System – was designed with 3 principles in mind, offering:

Predictable, Uniform Dosing

Repeatedly deliver therapy in a controlled, defined ablation zone at consistent temperatures to induce destruction of diseased tissue

Tolerable Pain, Minimal Complications

Create a therapeutic tool with low rates of complication and that is well-tolerated by patients immediately post-procedure, as well as subsequent days following therapy

Portability

Design a system that requires no expensive capital investment and offers portability among endoscopy suites at the hospital

The largest, singular area of investment for the company is clinical research with the goal of validating the principles above and supporting data collection and analysis. To accomplish this, C2 Therapeutics has completed or is in follow-up stages of:

C2 Therapeutics’ overall clinical experience using the CryoBalloon includes over 850 procedures from a combination of clinical trials and clinical practice.

To learn more about our clinical trials and which support the product goals outlined above, CLICK HERE to review our Clinical Data Summary.

If you prefer to learn more about open trials currently enrolling, please visit our trial listing on the ClinicalTrials.gov website.

MKTG 1066 REV A